Overview of Odactra
What is Odactra? Defining the Immunological Agent
| Property | Description |
|---|---|
| Active ingredient | House Dust Mite Allergen Extract |
| Form | Sublingual tablet (lyophilized) |
| Pharmacological class | Allergen Immunotherapy (AIT) |
| Common use | Disease modification in dust mite allergy |
| Origin | Modified biological product (mite cultures) |
Odactra is a prescription biological product whose active ingredient is House Dust Mite Allergen Extract, classified as an Allergenic Extract. It belongs to the therapeutic category of Allergen Immunotherapy (AIT), which is a specialized, long-term form of treatment designed to alter the core allergic disease process. Odactra is indicated for individuals aged 5 through 65, defining a distinct patient group for this therapy.
Unlike traditional medications intended for immediate symptom relief, such as antihistamines, AIT functions as a disease-modifying therapy. The general therapeutic purpose is to address the underlying cause of the allergy by gradually reprogramming the immune system's response to the specific allergen, fostering the long-term goal of immune tolerance.
Composition and Form: A Standardized Sublingual Tablet
The active component is derived from standardized extracts of the two primary house dust mite species, Dermatophagoides farinae and Dermatophagoides pteronyssinus, making it a modified natural extract. This extract contains specific allergen proteins, such as Der p 1 and Der f 1, which are crucial for the therapy’s intended effect.
Odactra is supplied as a lyophilized sublingual tablet for sublingual administration—that is, the tablet is placed under the tongue where it rapidly dissolves. The extract is standardized using a method known as SQ-HDM, which ensures consistent potency and allergen content between batches. This quality control measure is a functional requirement for immunotherapy and is a key feature of regulated AIT products.
Odactra’s Therapeutic Strategy: Tolerance, Not Symptom Relief
The central strategy of the therapy is the induction of tolerance through controlled, sustained exposure to the specific mite allergens. This process involves shifting the immune system's activity away from immediate, inflammatory reactions toward a less reactive state. This sustained desensitization process is key to the therapeutic goal.
This approach is focused on achieving a sustained desensitization to the mite proteins, which aims to reduce the severity of the body’s allergic responses to subsequent natural environmental exposure. This mechanism supports its role as a therapeutic tool aimed at reducing the underlying hypersensitivity over the long term, rather than providing temporary symptomatic relief.
Regulatory References
